Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy

Author(s): Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, et al.

Abstract

Background: We recently reported the safety and feasibility of autologous bone marrow mononuclear cell (ABMMNC) injection into areas of ischemic myocardium in patients with end-stage ischemic cardiomyopathy. The present study evaluated the safety and efficacy of this therapy at 6- and 12-month follow-up.

Methods and results: Twenty patients with 6- and 12-month follow-up (11 treated subjects; 9 controls) were enrolled in this prospective, nonrandomized, open-label study. Complete clinical and laboratory evaluations as well as exercise stress (ramp treadmill), 2-dimensional Doppler echocardiography, single-photon emission computed tomography (SPECT) perfusion scanning, and 24-hour Holter monitoring were performed at baseline and follow-up. Transendocardial delivery of ABMMNCs was performed with the aid of electromechanical mapping to identify viable myocardium. Each patient received 15 ABMMNC injections of 0.2 mL each. At 6 and 12 months, total reversible defect, as measured by SPECT perfusion scanning, was significantly reduced in the treatment group as compared with the control group. At 12 months, exercise capacity was significantly improved in the treatment group. This improvement correlated well with monocyte, B-cell, hematopoietic progenitor cell, and early hemapoietic progenitor cell phenotypes.

Conclusions: The 6- and 12-month follow-up data in this study suggest that transendocardial injection of ABMMNCs in patients with end-stage ischemic heart disease may produce a durable therapeutic effect and improve myocardial perfusion and exercise capacity.

Similar Articles

Neurological emergencies: acute stroke

Author(s): Davenport R, Dennis M

Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke

Author(s): Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, et al.

REACH: clinical feasibility of a rural telestroke network

Author(s): Hess DC, Wang S, Hamilton W, Lee S, Pardue C, et al.

Remote evaluation of acute ischemic stroke in rural community hospitals in Georgia

Author(s): Wang S, Gross H, Lee SB, Pardue C, Waller J, et al.

Gene therapy, cell transplantation and stroke

Author(s): Borlongan CV, Fournier C, Stahl CE, Yu G, Xu L, et al.

Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke

Author(s): Matsukawa N, Yasuhara T, Hara K, Xu L, Maki M, et al.

The albumin in acute stroke trial (ALIAS); design and methodology

Author(s): Hill MD, Moy CS, Palesch YY, Martin R, Dillon CR, et al.

Grafting neural stem cells improved the impaired spatial recognition in ischemic rats

Author(s): Toda H, Takahashi J, Iwakami N, Kimura T, Hoki S, et al.

Adult rat and human bone marrow stromal cells differentiate into neurons

Author(s): Woodbury D, Schwarz EJ, Prockop DJ, Black IB

Bone marrow as a source of endothelial cells and NeuN-expressing cells After stroke

Author(s): Hess DC, Hill WD, Martin-Studdard A, Carroll J, Brailer J, et al.

Intravenous versus intrastriatal cord blood administration in a rodent model of stroke

Author(s): Willing AE, Lixian J, Milliken M, Poulos S, Zigova T, et al.

Origin of endothelial progenitors in human postnatal bone marrow

Author(s): Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, et al.

Autologous bone marrow stem cell neurotransplantation in stroke patients

Author(s): Suárez-Monteagudo C, Hernández-Ramírez P, Alvarez-González L, García-Maeso I, de la Cuétara-Bernal K, et al.

Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli

Author(s): Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, et al.

Engineering mesenchymal stem cells for immunotherapy

Author(s): Jorgensen C, Djouad F, Apparailly F, Noël D

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

Author(s): Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, et al.

Ischaemic brain oedema

Author(s): Ayata C, Ropper AH

Inflammation markers and prediction of post-stroke vascular disease recurrence: the MITICO study

Author(s): Castillo J, Alvarez-Sabín J, Martínez-Vila E, Montaner J, Sobrino T, et al.

Proinflammatory cytokines and early neurological worsening in ischemic stroke

Author(s): Vila N, Castillo J, Dávalos A, Chamorro A

Mechanisms of ischemic brain damage

Author(s): Doyle KP, Simon RP, Stenzel-Poore MP

Evidence for circulating bone marrow-derived endothelial cells

Author(s): Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, et al.

Reduced number of circulating endothelial progenitors and HOXA9 expression in CD34+ cells of hypertensive patients

Author(s): Pirro M, Schillaci G, Menecali C, Bagaglia F, Paltriccia R, et al.

Bone marrow endothelial progenitors are defective in systemic sclerosis

Author(s): Del Papa N, Quirici N, Soligo D, Scavullo C, Cortiana M, et al.

Defective vasculogenesis in systemic sclerosis

Author(s): Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y

Impaired progenitor cell activity in age-related endothelial dysfunction

Author(s): Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, et al.

Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers

Author(s): Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, et al.

Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia

Author(s): Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, et al.

Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs

Author(s): Madeddu P, Emanueli C, Pelosi E, Salis MB, Cerio AM, et al.

Endothelial progenitor cell research in stroke: a potential shift in pathophysiological and therapeutical concepts

Author(s): Rouhl RP, van Oostenbrugge RJ, Damoiseaux J, Tervaert JW, Lodder J

Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting

Author(s): Mocini D, Staibano M, Mele L, Giannantoni P, Menichella G, et al.

Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure

Author(s): Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, et al.

Unchain my heart: the scientific foundations of cardiac repair

Author(s): Dimmeler S, Zeiher AM, Schneider MD

Circulating CD34-positive cells provide an index of cerebrovascular function

Author(s): Taguchi A, Matsuyama T, Moriwaki H, Hayashi T, Hayashida K, et al.

Endothelial progenitor cells during cerebrovascular disease

Author(s): Ghani U, Shuaib A, Salam A, Nasir A, Shuaib U, et al.